RA Capital Management Reports New 6.3% Stake in Sana Biotechnology, Inc.

On May 21, 2026, RA Capital Management, L.P., along with Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P., filed a Schedule 13G indicating a new substantial position in Sana Biotechnology, Inc. (SANA). The reporting persons collectively beneficially own 18,750,000 shares of common stock, representing approximately 6.3% of the class. This ownership percentage is based on a total of 299,899,468 shares outstanding as of May 14, 2026, which includes shares recently issued via an at-the-market offering. RA Capital serves as the investment adviser to the Fund and shares voting and dispositive power over the securities. The filing specifies that the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer. This initial filing marks a significant investment by the Boston-based healthcare investment firm in the Seattle-based biotechnology company.